Abstract: The new blueberry plant variety ‘IBUGA002’ is provided. ‘IBUGA002’ is a commercial variety that does not require chilling hours. The variety is produced from open pollination of the ‘TH-909’ variety (not patented). ‘IBUGA002’ displays a semi-erect to prostrate plant with strong vigor, provides early berry ripening, displays clustered inflorescence, and exhibits large fruit that are firm.

Abstract: Disclosed herein are wirelessly powered tissue ablation devices comprising an alternating magnetic field generator; an ablation probe comprising an ablation tip; a catheter comprising an opening at a tissue insertion end and a lumen extending along a length of the catheter to the catheter opening; and a magnetic field receiving coil configured to be electrically coupled to the ablation probe; wherein at least a portion of the ablation probe is positionable within the lumen of the catheter, and wherein the ablation tip protrudes through the opening of the catheter. Also disclosed are methods of using wirelessly powered tissue ablation devices.

Abstract: Nanoparticles and formulations for preventing or reducing peri-/post-menopausal bone loss and/or obesity in a subject are disclosed. The nanoparticles contain a cage, such as a zeolitic imidazolate framework (“ZIF”), a surface modifying agent, a targeting ligand, and an active agent. The surface modifying agent is attached to the outer surface of the cage and the targeting ligand is exposed to the surrounding environment. The active agent is encapsulated in the cage. The targeting ligand binds to a reproductive hormone or a receptor of a reproductive hormone. The active agent can be a ribosome inactivating protein, an apoptosis inducer, a hormone, a receptor ligand, or a nucleic acid, or a combination thereof, that inactivate ribosomes of gonadotroph cells and/or prevent or reduce secretion of follicle-stimulating hormones in the subject. Uses for formulations incorporating the nanoparticles for preventing or reducing peri-/post-menopausal bone loss and/or obesity in a subject are also disclosed.

Abstract: Disclosed herein are neural extracellular vesicles (EVs) and methods of using these EVs in the treatment of spinal cord injury, stroke, and traumatic brain injury and neurodegenerative diseases.

Abstract: The new blueberry plant variety ‘IBUGA001’ is provided. ‘IBUGA001’ is a commercial variety. The variety is produced from open pollination of the ‘TH-909’ variety (not patented). ‘IBUGA001’ displays a semi-erect to prostrate plant with strong vigor, provides very early berry ripening, and exhibits large fruit with medium sweetness and medium firmness.

Abstract: A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

Abstract: Provided herein are non-naturally occurring, broadly reactive, pan-epitopic antigens derived from H3 influenza virus that are immunogenic and are capable of eliciting a broadly reactive immune response, such as a broadly reactive neutralizing antibody response, against H3 virus following introduction into a subject. Also provided are non-naturally, broadly reactive occurring immunogens, vaccines, virus-like particles (VLPs) and compositions comprising the immunogens and vaccines. Methods of generating an immune response in a subject by administering the immunogens, vaccines, VLPs, or compositions thereof are provided. In particular, the immunogens comprise the hemagglutinin (HA) protein of H3 influenza virus strains.

Abstract: Provided herein are long-acting antiparasitic devices comprising parasiticidal isoxazoline active agent for external use on an animal to treat and/or prevent parasitic infestations by ectoparasites, and in some embodiments, also parasitic infections. The disclosure also describes methods and uses of the antiparasitic external devices to treat and/or prevent parasitic infestations and/or infections in an animal.

Abstract: Disclosed herein are oligosaccharides and intermediates useful for the production thereof. The compounds are useful as analytical standards and as intermediates for the preparation of more complex oligosaccharide and N-glycan products. The compounds may be prepared in high purity using the selective stop/go synthetic methods disclosed herein.

Abstract: Described herein are home compostable adhesives composed of a polyester. The adhesives described herein have widespread commercial applicability as a compostable alternative to current non-biodegradable adhesives such as, for example, pressure sensitive adhesives. In one aspect, the polyester includes a plurality of residues of a diol selected from the group consisting of 1,3-propanediol, 1,4-butanediol, or a combination thereof; a plurality of residues of a first dicarboxylic consisting of succinic acid; a plurality of residues of a second dicarboxylic consisting of glutaric acid; and a plurality of residues of a sugar.

Abstract: Disclosed herein are neural extracellular vesicles (EVs) and methods of using these EVs in the treatment of spinal cord injury, stroke, and traumatic brain injury and neurodegenerative disease.

Abstract: The three main peripheral sensory neuron (SN) subtypes, nociceptors, mechanoreceptors, and proprioceptors localize to dorsal root ganglia (DRG) and convey sensations such as pain, temperature, pressure and limb movement/position. Disclosed herein is a chemically defined differentiation protocol that generates all three SN subtypes from the same starting population, as well as methods to enrich for each individual subtypes. The protocol yields high efficiency and purity cultures that are electrically active and respond to specific stimuli. Their molecular character and maturity stage are described and evidence for their use as an axotomy model is exemplified. Cell populations and compositions formed from the resulting cells, as well as methods of their use for disease treatment, drug screening, and modeling of human disorders affecting SNs are also provided.

Abstract: Disclosed herein are compositions and methods for cellular reconstitution of photopolymerized, lyophilized, bioactive chondroitin sulfate glycosaminoglycan (CS-GAG)-based hydrogel matrices.

Abstract: The present invention relates to methods of replicating viruses in vitro. In particular, the invention relates to a genetically modified population of cells, and/or a population of cells treated with an exogenous compound, wherein the cells are capable of producing more virus than cells lacking the genetic modification and/or lacking treatment with the exogenous compound. The invention also relates to methods of producing populations of such cells, as well as the use of the viruses obtained to prepare vaccine compositions.

Abstract: Provided herein are microscopes providing multi-directional illumination of a sample volume by alternately reflecting a light sheet exiting a single objective lens off of multiple reflectors positioned about the sample volume. The provided microscopes exhibit high lateral and axial resolution and are particularly useful for imaging thick samples. Also provided are methods and computer instructions and systems for using the provided microscopes.

Abstract: Compositions and methods for modulating HIF-2? to meditate of hypoxia signaling in satellite cells and applications thereof for improving skeletal muscle generation and repair are provided. For example, methods of enhancing, increasing, accelerating or/and otherwise improving skeletal muscle generation or regeneration in a subject in need thereof are disclosed. In some embodiments, the methods include administering the subject an effective amount of HIF-2? inhibitor. The HIF-2? inhibitor can be effective to, for example, increase muscle satellite cell proliferation, differentiation, or a combination thereof in a subject. Composition and methods for improving respiration, and reducing or preventing the development or progression of fibrosis are also provided. The disclosed compositions and methods are particularly useful for treating muscular dystrophies, myopathies, and other muscle-related diseases and disorders.

Abstract: Recombinant viral class I fusion proteins that favor a prefusion conformational state over a postfusion conformational state, polynucleotides encoding same, vaccines comprising the proteins or polynucleotides, and methods of vaccination with the vaccines. The recombinant proteins include recombinant RSV F proteins, recombinant hMPV proteins, and recombinant SARS-COV-2 S proteins.

Abstract: A new and distinct cultivar of Ilex plant named ‘RutHol8’ is characterized by a combination of its upright, v-shaped growth habit, its attractive reddish new growth, its intermediate height:width ratio, and its resistance to spider mites.

Abstract: A new and distinct cultivar of Ilex plant named ‘RutHol10’ is characterized by a combination of its unique globose habit for plants with this parentage, leaf coloration and upright leaf angle that give ‘RutHol10’ more of a boxwood (Buxus) appearance, and its higher tolerance of spider mites than other I. crenata cultivars.

Abstract: A new and distinct cultivar of the Vitex agnus-castus plant named ‘V12-2-1’ is characterized by a combination of its heavy blooming with violet-blue flowers, its compact form, its short panicle length with closely spaced subpanicles and whoris of florets, and its tendency to re-bloom in late summer or fall.